{"id":57715,"date":"2026-02-24T15:58:16","date_gmt":"2026-02-24T07:58:16","guid":{"rendered":"https:\/\/flcube.com\/?p=57715"},"modified":"2026-02-24T15:58:17","modified_gmt":"2026-02-24T07:58:17","slug":"gilead-sciences-to-acquire-arcellx-for-7-8b-bolsters-car-t-pipeline-with-bcma-targeted-anito-cel","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57715","title":{"rendered":"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel"},"content":{"rendered":"\n<p><strong>Gilead Sciences Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ:\u202fGILD<\/a>)<\/strong> announced a definitive agreement to acquire <strong>Arcellx Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/ACLX:NASDAQ\">NASDAQ:\u202fACLX<\/a>)<\/strong> for <strong>USD\u202f115.00 per share in cash<\/strong> at closing, plus a <strong>contingent value right (CVR) of USD\u202f5.00 per share<\/strong>. The transaction implies an <strong>equity value of USD\u202f7.8 billion<\/strong> based on the closing payment. The deal strengthens Gilead&#8217;s position in the <strong>cell therapy<\/strong> market through Arcellx&#8217;s lead asset, <strong>anitocabtagene autoleucel (anito\u2011cel)<\/strong>, a BCMA\u2011targeted CAR\u2011T therapy for multiple myeloma.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Gilead Sciences Inc. (NASDAQ:\u202fGILD)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Arcellx Inc. (NASDAQ:\u202fACLX)<\/td><\/tr><tr><td><strong>Cash Consideration<\/strong><\/td><td>USD\u202f115.00 per share at closing<\/td><\/tr><tr><td><strong>Contingent Value Right (CVR)<\/strong><\/td><td>USD\u202f5.00 per share<\/td><\/tr><tr><td><strong>Implied Equity Value<\/strong><\/td><td><strong>USD\u202f7.8 billion<\/strong><\/td><\/tr><tr><td><strong>Strategic Asset<\/strong><\/td><td>Anito\u2011cel (BCMA\u2011targeted CAR\u2011T for multiple myeloma)<\/td><\/tr><tr><td><strong>Prior Relationship<\/strong><\/td><td>Kite\/Gilead and Arcellx existing collaboration on anito\u2011cel<\/td><\/tr><tr><td><strong>Board Approval<\/strong><\/td><td>Approved by both Gilead and Arcellx boards<\/td><\/tr><tr><td><strong>Expected Closing<\/strong><\/td><td>Q2\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-asset-anito-cel\">Strategic Asset \u2013 Anito\u2011cel<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Anitocabtagene autoleucel (anito\u2011cel)<\/strong> \u2013 investigational BCMA\u2011targeted CAR\u2011T cell therapy<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>B\u2011cell maturation antigen (BCMA)<\/strong> \u2013 validated target in multiple myeloma<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Treatment of patients with <strong>multiple myeloma<\/strong><\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Jointly developed and commercialized under existing Kite\u2011Arcellx collaboration<\/li>\n\n\n\n<li><strong>Rationale:<\/strong> Adds next\u2011generation CAR\u2011T asset to Gilead&#8217;s cell therapy portfolio, complementing Yescarta and Tecartus<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CAR\u2011T Portfolio Expansion:<\/strong> The acquisition integrates Arcellx&#8217;s <strong>anito\u2011cel<\/strong> into Gilead&#8217;s cell therapy franchise, creating a <strong>comprehensive multiple myeloma<\/strong> offering alongside existing lymphoma therapies.<\/li>\n\n\n\n<li><strong>Synergy with Kite:<\/strong> The deal formalizes and deepens the existing <strong>Kite\u2011Arcellx collaboration<\/strong>, streamlining development and commercialization of anito\u2011cel under unified ownership.<\/li>\n\n\n\n<li><strong>Market Positioning:<\/strong> BCMA\u2011targeted CAR\u2011T therapies represent a <strong>high\u2011growth segment<\/strong> in multiple myeloma, with established clinical validation and significant unmet medical need in relapsed\/refractory patients.<\/li>\n\n\n\n<li><strong>Financial Structure:<\/strong> The <strong>CVR component<\/strong> ties additional shareholder value to future milestones, aligning Arcellx investors with post\u2011closing clinical and commercial success.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cell Therapy Consolidation:<\/strong> The deal signals continued <strong>M&amp;A momentum<\/strong> in the CAR\u2011T space as large biopharma seeks to secure next\u2011generation assets amid intensifying competition.<\/li>\n\n\n\n<li><strong>Multiple Myeloma Landscape:<\/strong> Gilead gains a <strong>potential best\u2011in\u2011class BCMA CAR\u2011T<\/strong> to compete with Bristol Myers Squibb&#8217;s Abecma and Legend Biotech\/J&amp;J&#8217;s Carvykti.<\/li>\n\n\n\n<li><strong>Shareholder Value:<\/strong> The <strong>$7.8B equity value<\/strong> represents a significant premium, reflecting Arcellx&#8217;s strategic value and anito\u2011cel&#8217;s commercial potential.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the expected closing of the Gilead\u2011Arcellx transaction, regulatory approvals, and commercial expectations for anito\u2011cel. Actual results may differ due to risks including antitrust clearance, integration challenges, and clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences Inc. (NASDAQ:\u202fGILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ:\u202fACLX) for USD\u202f115.00&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57716,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1945,16,21,77,226,1946,1025],"class_list":["post-57715","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-arcellx","tag-cancer","tag-car-t","tag-cell-therapy","tag-gilead-sciences","tag-nasdaq-aclx","tag-nasdaq-gild"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences Inc. (NASDAQ:\u202fGILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ:\u202fACLX) for USD\u202f115.00 per share in cash at closing, plus a contingent value right (CVR) of USD\u202f5.00 per share. The transaction implies an equity value of USD\u202f7.8 billion based on the closing payment. The deal strengthens Gilead&#039;s position in the cell therapy market through Arcellx&#039;s lead asset, anitocabtagene autoleucel (anito\u2011cel), a BCMA\u2011targeted CAR\u2011T therapy for multiple myeloma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57715\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences Inc. (NASDAQ:\u202fGILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ:\u202fACLX) for USD\u202f115.00 per share in cash at closing, plus a contingent value right (CVR) of USD\u202f5.00 per share. The transaction implies an equity value of USD\u202f7.8 billion based on the closing payment. The deal strengthens Gilead&#039;s position in the cell therapy market through Arcellx&#039;s lead asset, anitocabtagene autoleucel (anito\u2011cel), a BCMA\u2011targeted CAR\u2011T therapy for multiple myeloma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57715\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T07:58:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T07:58:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2402.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57715#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57715\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel\",\"datePublished\":\"2026-02-24T07:58:16+00:00\",\"dateModified\":\"2026-02-24T07:58:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57715\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57715#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2402.webp\",\"keywords\":[\"Arcellx\",\"Cancer\",\"CAR-T\",\"Cell-therapy\",\"Gilead Sciences\",\"NASDAQ: ACLX\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57715#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57715\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57715\",\"name\":\"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57715#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57715#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2402.webp\",\"datePublished\":\"2026-02-24T07:58:16+00:00\",\"dateModified\":\"2026-02-24T07:58:17+00:00\",\"description\":\"Gilead Sciences Inc. (NASDAQ:\u202fGILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ:\u202fACLX) for USD\u202f115.00 per share in cash at closing, plus a contingent value right (CVR) of USD\u202f5.00 per share. The transaction implies an equity value of USD\u202f7.8 billion based on the closing payment. The deal strengthens Gilead's position in the cell therapy market through Arcellx's lead asset, anitocabtagene autoleucel (anito\u2011cel), a BCMA\u2011targeted CAR\u2011T therapy for multiple myeloma.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57715#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57715\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57715#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2402.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2402.webp\",\"width\":1080,\"height\":608,\"caption\":\"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57715#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences Inc. (NASDAQ:\u202fGILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ:\u202fACLX) for USD\u202f115.00 per share in cash at closing, plus a contingent value right (CVR) of USD\u202f5.00 per share. The transaction implies an equity value of USD\u202f7.8 billion based on the closing payment. The deal strengthens Gilead's position in the cell therapy market through Arcellx's lead asset, anitocabtagene autoleucel (anito\u2011cel), a BCMA\u2011targeted CAR\u2011T therapy for multiple myeloma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57715","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel","og_description":"Gilead Sciences Inc. (NASDAQ:\u202fGILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ:\u202fACLX) for USD\u202f115.00 per share in cash at closing, plus a contingent value right (CVR) of USD\u202f5.00 per share. The transaction implies an equity value of USD\u202f7.8 billion based on the closing payment. The deal strengthens Gilead's position in the cell therapy market through Arcellx's lead asset, anitocabtagene autoleucel (anito\u2011cel), a BCMA\u2011targeted CAR\u2011T therapy for multiple myeloma.","og_url":"https:\/\/flcube.com\/?p=57715","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-24T07:58:16+00:00","article_modified_time":"2026-02-24T07:58:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2402.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57715#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57715"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel","datePublished":"2026-02-24T07:58:16+00:00","dateModified":"2026-02-24T07:58:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57715"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57715#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2402.webp","keywords":["Arcellx","Cancer","CAR-T","Cell-therapy","Gilead Sciences","NASDAQ: ACLX","NASDAQ: GILD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57715#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57715","url":"https:\/\/flcube.com\/?p=57715","name":"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57715#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57715#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2402.webp","datePublished":"2026-02-24T07:58:16+00:00","dateModified":"2026-02-24T07:58:17+00:00","description":"Gilead Sciences Inc. (NASDAQ:\u202fGILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ:\u202fACLX) for USD\u202f115.00 per share in cash at closing, plus a contingent value right (CVR) of USD\u202f5.00 per share. The transaction implies an equity value of USD\u202f7.8 billion based on the closing payment. The deal strengthens Gilead's position in the cell therapy market through Arcellx's lead asset, anitocabtagene autoleucel (anito\u2011cel), a BCMA\u2011targeted CAR\u2011T therapy for multiple myeloma.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57715#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57715"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57715#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2402.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2402.webp","width":1080,"height":608,"caption":"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57715#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences to Acquire Arcellx for $7.8B \u2013 Bolsters CAR\u2011T Pipeline with BCMA\u2011Targeted Anito\u2011cel"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2402.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57715"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57715\/revisions"}],"predecessor-version":[{"id":57717,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57715\/revisions\/57717"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57716"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}